Patrick Cohen

Sanofi (France) — France

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index839citations73works8.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Angiogenesis and VEGF in Cancer(19), Advanced Breast Cancer Therapies(17), Cancer Treatment and Pharmacology(13), HER2/EGFR in Cancer Research(11), Estrogen and related hormone effects(9)

Publications73 total

Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Primary Results From AMEERA-5
Journal of Clinical Oncology·2024· 14 cited
Joint modeling of tumor dynamics and progression‐free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I–II trials
CPT Pharmacometrics & Systems Pharmacology·2024· 3 citedOpen Access
Reply to Y. Yoshitomi et al
Journal of Clinical Oncology·2023
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Journal of Clinical Oncology·2023· 67 citedOpen Access
Supplementary Video 2 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Data from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Supplementary Video 3 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Supplementary Table 1, Figures 1-8, Movie Legends 1-4 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Data from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Supplementary Video 3 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Supplementary Video 1 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Supplementary Video 4 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Supplementary Table 1, Figures 1-8, Movie Legends 1-4 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Supplementary Video 1 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Supplementary Video 2 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Supplementary Video 4 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Data from Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Fig. S1 from Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure Legends from Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Fig. S2 from Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Jean‐Charles Soria(17), Françoise Farace(17), Anthony W. Tolcher(10), Cristiana Sessa(9), Nathalie Lassau(9), Rastislav Bahleda(9), Marie Hospitel(9), Christine Veyrat‐Follet(9), Mélissa Taylor(8), Fanny Billiot(8), Virginie Marty(8), Valérie Rouffiac(8), Elodie Tournay(8), Paule Opolon(8), Fawzia Louache(8), Gilles Vassal(8), Corinne Laplace‐Builhé(8), Philippe Vielh(8), Aditya Bardia(8), Sylvaine Cartot‐Cotton(8)